Importantly, this resistance to SHP2 inhibition may also occur in KRAS or BRAF mutant cancers wherein FGFRs are feedback activated due to MAPK inhibition, as evidenced by the observations in SW1736 cells (Supplementary Figure 6A). The gene discussed is KRAS; the disease is cancer.